The sunset of somatic genetics and the dawn of epigenetics: A new frontier in pancreatic cancer research

Current Opinion in Gastroenterology

Volumn 24, Issue 5, 2008, Pages 597-602

  Lomberk, Gwen ^a   Mathison, Angela J ^a   Grzenda, Adrienne ^a   Urrutia, Raul ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chromatin modifying proteins; Epigenetics; Heterochromatin protein 1; Pancreatic cancer; Polycomb

Indexed keywords

3 DEAZANEPLANOCIN A; 4 N ACETYLDINALINE; ANTINEOPLASTIC AGENT; APICIDIN; AZACITIDINE; BIX 01294; CYCLOPAMINE; DIAZEPINE DERIVATIVE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EPOXIDE; FR 235222; GEMCITABINE; HETEROCHROMATIN PROTEIN 1; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; IMATINIB; POLYCOMB GROUP PROTEIN; SK 7068; SULINDAC SULFONE; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER RESEARCH; CARCINOGENESIS; CHEMOPROPHYLAXIS; CHROMATIN; CHRONIC PANCREATITIS; CLINICAL TRIAL; DEACETYLATION; DNA METHYLATION; DRUG POTENTIATION; EPIGENETICS; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PANCREAS CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

CELL CYCLE PROTEINS; DNA METHYLATION; EPIGENESIS, GENETIC; FORECASTING; GENE THERAPY; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PANCREATIC NEOPLASMS; RESEARCH;

EID: 55549090720     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32830b111d     Document Type: Review

References (32)

1. Singh M, Maitra A. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 2007; 7:9-19. Outstanding review covering key aspects of the biology and pathobiology of early pancreatic preneoplastic lesions.
2. Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005; 70:65-72.
3. Allis CD, Jenuwein T, Reinberg D, Caparros ML, editors. Epigenetics. 1 st ed. Cold Spring Harbor Laboratory Press; 2007. 507 p. Recently released outstanding book, which covers from basic to advanced molecular concepts of epigenetics.
4. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-1159. An excellent review offering a robust description of DNA methylation.
5. Cheng X, Blumenthal RM. Mammalian DNA methyltransferases: a structural perspective. Structure 2008; 16:341-350.
6. Mund C, Brueckner B, Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 2006; 1:7-13.
7. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008; 45:23-30.
8. Fernandez-Zapico ME, Molina JR, Ahlquist D, Urrutia R. Functional characterization of KFL11, a novel TGFβ-regulated tumor suppressor for pancreatic cancer. Pancreatology 2003; 3:429-441.
9. Gebhard C, Schwarzfischer L, Pham TH, et al. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res 2006; 66:6118-6128.
10. Rosty C, Geradts J, Sato N, et al. p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol 2003; 27:1495-1501.
11. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63:3735-3742.
12. Privalsky ML, editor. Transcriptional corepressors. 1st ed. Springer; 2001. 190 p.
13. Berger SL Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002; 12:142-148.
14. Hildmann C, Riester D, Schwienhorst A. Histone deacetylases - an important class of cellular regulators with a variety of functions. Appl Microbiol Biotechnol 2007; 75:487-497.
15. Bruserud O, Stapnes C, Ersvaer E, et al. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Curr Pharm Biotechnol 2007; 8:388-400.
16. Glaser KB, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2:151-163.
17. Pan L, Lu J, Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 2007; 4:337-343.
18. Ouaïssi M, Cabrai S, Tavares J, et al. Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol Ther 2007; 7.
19. Donadelli M, Costanzo C, Beghelli S, et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trlchostatin A and gemcitabine. Biochim Biophys Acta 2007; 1773:1095-1106. This study offers a solid proof-of-principle on the utility of combining HDACIs with gemcitibine (the first line of treatment for patients affected by pancreatic cancer) to reach a synergistic effect.
20. Singh EK, Ravula S, Pan CM, et al. Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: a cyclic tetrapeptide scaffold. Bioorg Med Chem Lett 2008; 18:2549-2554.
21. Breiling A, Sessa L, Orlando V, Kwang WJ. Biology of polycomb and trithorax group proteins, Int Rev Cytol 2007; 258:83-136.
22. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 2002; 298:1039-1043.
23. Ringrose L. Polycomb comes of age: genome-wide profiling of target sites. Curr Opin Cell Biol 2007; 19:290-297.
24. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21:1050-1063. This study constitutes the first description of a pharmacological agent that can directly affect polycomb complexes. While exciting, additional experiments must be done to define the specificity of the drug described. The data serve as a reminder of the fact that, similar to DNA methylation, long-term chromatin-mediated epigenetic changes can be reversible, a fact of great benefit when trying to reactivate tumor suppressor genes.
25. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006; 66:6063-6071.
26. Shi B, Liang J, Yang X, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007; 27:5105-5119.
27. Grzenda AL, Lomberk G, Urrutia R. Different EZH2 isoforms are expressed in pancreatic cells: evidence for a polycomb-mediated subcode within the context of the histone code. Pancreas 2007; 35:404.
28. Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008 [Epub ahead of print]. This study looks at tri-methyl-K27 histone H3 as a predictor of poor outcome in pancreatic cancer. This work also supports the idea that polycomb complexes, which bind to this epigenetic mark, may play a key role in pancreatic cancer development and progression.
29. Lomberk G, Wallrath L, Urrutia R. The heterochromatin protein 1 family. Genome Biol 2006; 7:228.
30. Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007; 25:473-481. This is another example of the use of small drugs to target epigenetic complexes that are Involved in gene silencing, potentially of tumor suppressor genes. The inhibitor described in this study targets the HP1-mediating silencing system. As polycomb and HP1 may together be the most important system for silencing tumor suppressor genes, it would be interesting to define whether drugs against both systems synergize.
31. Lomberk G, Bensi D, Fernandez-Zapico ME, Urrutia R. Evidence for the existence of an HP1-mediated subcode within the histone code. Nat Cell Biol 2006; 8:407-415.
32. Lomberk G, Urrutia R. The family feud: turning off Sp1 by Sp1-like proteins. Biochem J 2005; 392:1-11.